Mebendazole (R 17635) in enterobiasis. A clinical trial in mental retardates.

The efficacy of mebendazole against enterobiasis was tested on 150 institutionalized mental retardates (range 5-25 years). At the start of the trial all patients swallowed on tablet containing 100 mg mebendazole. Another tablet was administered to all patients 2 weeks and 1, 2 and 3 months later. 19 patients were further treated with one tablet 4 and 5 months after the start of the trial. The presence of E. vermicularis was checked with cellophane adhesive tapes from the anal skin and from the right-hand finger-tips before the trial and after 1, 3 and 6 months. 94 subjects were positive before the trial. At the first post-treatment examination, all patients were found negative. However, 12% were reinfected. No side effects were observed or reported.
AuthorsJ A Lormans, A J Wesel, O F Vanparus
JournalChemotherapy (Chemotherapy) Vol. 21 Issue 3-4 Pg. 255-60 ( 1975) ISSN: 0009-3157 [Print] SWITZERLAND
PMID1157575 (Publication Type: Journal Article)
Chemical References
  • Benzimidazoles
  • Mebendazole
  • Adolescent
  • Adult
  • Benzimidazoles (therapeutic use)
  • Child
  • Child, Preschool
  • Drug Evaluation
  • Enterobius (isolation & purification)
  • Female
  • Humans
  • Intellectual Disability
  • Male
  • Mebendazole (therapeutic use)
  • Oxyuriasis (drug therapy, microbiology)
  • Pregnancy
  • Recurrence
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: